– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $29.9 Billion – – Net Income of $2.3 Million – – Increased EBITDA[*] to $5.4 Million from $2.0 Million in the Prior Year – NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent fina ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-41991 Binah Capital Group, Inc. (Exact name of registrant as specified in its charter) | Delaw ...

Exhibit 99.1 BINAH CAPITAL GROUP REPORTS RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025 - Grew Total Revenue 11% Year-over-Year to $187.1 Million - - Assets Under Management ("AuM") Increased 11% Year-over-Year to $29.9 Billion - "We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform," stated Craig Gould, Chief Executive Officer of Binah Capital Group. "The momentum we have created through our growth ...

Core Insights - Relmada Therapeutics announced promising 12-month interim data from its Phase 2 trial of NDV-01 for high-risk non-muscle invasive bladder cancer (NMIBC), showing a complete response (CR) rate of 76% and an 80% CR rate in the BCG-unresponsive population, indicating potential for a best-in-class profile [1][2][6] Clinical Results - The Phase 2 trial demonstrated a 12-month complete response rate of 76% in the overall population and 80% in the BCG-unresponsive subgroup [2][6] - The complete response rates at various time points were: 95% at any time, 87% at 3 months, 86% at 6 months, 85% at 9 months, and 76% at 12 months [4] - In the BCG-unresponsive subgroup, the complete response rates were 94% at any time, 82% at 3 months, 86% at 6 months, and 91% at 9 months [5] Safety Profile - NDV-01 exhibited a favorable safety profile with no patients experiencing Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations [6][12] - Among the 48 patients, 63% experienced treatment-related adverse events, primarily transient dysuria [12] Future Development Plans - The interim results support advancing NDV-01 into the Phase 3 RESCUE registrational program, expected to initiate in mid-2026, with two pathways: one for adjuvant intermediate-risk NMIBC and another for second-line BCG-unresponsive NMIBC [3][8] - The Phase 3 program aims to address significant unmet needs in the NMIBC market, particularly for patients with limited treatment options [13] Product Overview - NDV-01 is a sustained-release formulation of gemcitabine and docetaxel designed for intravesical administration, allowing for gradual drug release over 10 days [9] - The formulation is convenient to administer in approximately 5 minutes without the need for anesthesia or specialized equipment, enhancing its potential for broad adoption in clinical settings [9]

Core Insights - New data from the Phase 2b SunRISe-1 study indicate that over 95% of patients with high-risk, non-muscle invasive bladder cancer remained progression-free at one year, with more than 92% avoiding bladder removal surgery [1][2][3] Company Overview - Johnson & Johnson is committed to developing innovative treatments for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have limited options beyond radical cystectomy [2] - The company is focusing on the gemcitabine intravesical system, which has shown promising results in clinical trials for patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy [1][5] Study Details - Cohort 4 of the SunRISe-1 study involved 52 patients with papillary-only, high-risk NMIBC who did not respond to BCG therapy and were ineligible for or declined radical cystectomy [2][5] - The therapy was administered every three weeks for six months, followed by every 12 weeks for up to an additional 18 months [2] Efficacy Results - At a median follow-up of 15.9 months, the one-year disease-free survival (DFS) rate was 74.3%, with progression-free survival (PFS) at 95.6% and overall survival (OS) at 98% [3] - Notably, 92.3% of patients did not undergo radical cystectomy, indicating the treatment's potential to preserve bladder function [3] Safety Profile - The therapy was generally well-tolerated, with 80.8% of patients experiencing low-grade treatment-related side effects, primarily mild urinary symptoms [4] - Serious side effects were uncommon, occurring in 13.5% of patients, and no treatment-related deaths were reported [4] Industry Context - High-risk non-muscle invasive bladder cancer represents a significant challenge in oncology, with traditional treatment options often leading to radical cystectomy, which can severely impact patients' quality of life [2][7] - The ongoing need for effective bladder preservation therapies highlights the importance of studies like SunRISe-1 in addressing unmet medical needs in this patient population [2][7]

Core Insights - BINAH Capital Group has announced that a Chicago-based advisory group, recently acquired by Merit Financial Advisors, will utilize PKS Investments as its broker-dealer [1][2] - The Chicago-based team manages approximately $1.2 billion in client assets and will leverage PKS for its commission-based business [2] - PKS Investments offers a supportive broker-dealer framework tailored for independent Registered Investment Advisors (RIAs), providing a robust platform for growth [2][3] Company Overview - BINAH Capital Group operates as a financial services enterprise that supports independent financial advisors through its network of broker-dealers [3] - The company specializes in a hybrid-friendly model that delivers value to RIAs navigating the complex financial landscape [3] - BINAH's portfolio is designed to help advisors manage and execute commission-based business effectively while offering top-tier resources [3]

Core Insights - BINAH Capital Group's Chief Business Development & Engagement Officer, Ryan Marcus, has been named a Finalist in the ThinkAdvisor 2025 Luminaries Awards for Thought Leader of the Year [1] - The Luminaries Awards program recognizes firms and individuals setting new standards in financial services, emphasizing leadership, innovation, and measurable impact [2] - This recognition highlights BINAH's commitment to advisor growth, strategic business development, and thought leadership, enhancing best practices in the independent channel [3] Company Overview - BINAH Capital Group operates as a financial services enterprise that supports independent financial advisors through a network of broker-dealers [5] - The company specializes in a hybrid-friendly model, providing value to Registered Investment Advisors (RIAs) navigating complex financial landscapes [5] - BINAH aims to empower advisors by offering not just tools but also partnerships, delivering structure, flexibility, and innovative solutions to succeed in a competitive marketplace [5] Leadership Recognition - Craig Gould, CEO of BINAH, expressed honor in Ryan Marcus's nomination, reflecting the strength of the business development team and the organization's commitment to supporting independent financial professionals [4] - The winners of the Luminaries Awards will be selected by a panel of independent judges and celebrated at an event on December 4, 2025, in New York [4]

Core Viewpoint - Binah Capital Group will participate in the NobleCon21 conference on December 4, 2025, showcasing its commitment to empowering independent financial advisors [1]. Company Overview - Binah Capital Group is a financial services enterprise that operates a network of firms aimed at supporting independent financial advisors [3]. - The company specializes in a hybrid-friendly model as a national broker-dealer aggregator, providing innovative solutions for Registered Investment Advisors (RIAs) [3]. - Binah Capital focuses on delivering value through partnerships and resources that help advisors manage commission-based businesses effectively [3]. Event Details - The presentation at the NobleCon21 conference will be led by Craig Gould, CEO, and David Shane, CFO, at 9:30 AM ET [1]. - A webcast of the presentation will be available the following day on multiple platforms, including Binah Capital's investor relations website [2].

Group 1 - Binah Capital Group, Inc. (NASDAQ: BCG) reported a 9.5% increase in revenue to $46.2 million, driven by strong commissions, increased advisory fees, and higher interest income [1] - The company's assets under management (AUM) grew by 11% year-over-year to $30.0 billion, indicating the scalability of its advisor-centric business model [2] - Profitability reached a multi-quarter high with EBITDA increasing to $2.9 million, allowing for potential strategic investments to support advisors [3] Group 2 - Management expressed positive momentum heading into the fourth quarter, supported by advisor productivity and macro trends [4] - Despite increased volatility in shares, they settled almost flat and are trading at a 92% discount on a last twelve months price-to-sales ratio [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Premarket Gainers - Cidara Therapeutics, Inc. (CDTX) is up 91% at $203.18 - Binah Capital Group, Inc. (BCG) is up 45% at $2.07 - Invivyd, Inc. (IVVD) is up 42% at $2.52 - Omeros Corporation (OMER) is up 15% at $7.25 - The Oncology Institute, Inc. (TOI) is up 12% at $3.47 - AlphaVest Acquisition Corp (ATMV) is up 11% at $7.99 - ARB IOT Group Limited (ARBB) is up 7% at $7.31 - Hyperion DeFi, Inc. (HYPD) is up 6% at $5.27 - TruGolf Holdings, Inc. (TRUG) is up 6% at $2.02 - Boqii Holding Limited (BQ) is up 5% at $2.24 [3] Premarket Losers - TSS, Inc. (TSSI) is down 40% at $9.12 - StubHub Holdings, Inc. (STUB) is down 20% at $15.02 - ESS Tech, Inc. (GWH) is down 20% at $3.38 - Red Cat Holdings, Inc. (RCAT) is down 17% at $6.38 - WhiteFiber, Inc. (WYFI) is down 15% at $16.81 - New Era Energy & Digital, Inc. (NUAI) is down 13% at $3.66 - NET Power Inc. (NPWR) is down 11% at $2.62 - Korro Bio, Inc. (KRRO) is down 9% at $5.90 - Anavex Life Sciences Corp. (AVXL) is down 8% at $5.20 - Interactive Strength Inc. (TRNR) is down 5% at $2.47 [4]